Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jennifer, Talaty"'
Autor:
William D. Hanley, Yali Zhu, William L. Marshall, Luzelena Caro, Hwa-Ping Feng, Eric Mangin, Deborah Panebianco, Xiaobi Huang, Robert Valesky, Jennifer Talaty, Monika Martinho, Joan R. Butterton, Patricia Jumes, Christine Fandozzi, Zifang Guo, Wendy W. Yeh, Marian Iwamoto
Publikováno v:
Clinical Pharmacology in Drug Development. 8:962-970
Treatment of individuals coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) requires careful consideration of potential drug-drug interactions. We evaluated the pharmacokinetic interaction of the direct-acting antiviral ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a42966b426c387ac34b77c65f59795
https://doi.org/10.1002/cpdd.701
https://doi.org/10.1002/cpdd.701
Autor:
Marian Iwamoto, Wendy W. Yeh, Zifang Guo, Deborah Panebianco, Iain P. Fraser, Hwa-Ping Feng, Patricia Jumes, Lisa L. Ross, Joan R. Butterton, William L. Marshall, Christine Fandozzi, Luzelena Caro, Joanne Ma, Jennifer Talaty, Xiaobi Huang, Eric Mangin
Publikováno v:
Journal of Antimicrobial Chemotherapy. 74:710-717
Background Elbasvir/grazoprevir is a once-daily fixed-dose combination therapy for the treatment of chronic HCV infection, including HCV/HIV coinfection. Objectives To evaluate the pharmacokinetic interaction of elbasvir and grazoprevir with raltegra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4873366535c6572f14e5ea4fc70ce177
https://doi.org/10.1093/jac/dky465
https://doi.org/10.1093/jac/dky465
Autor:
Wendy W. Yeh, Iain P. Fraser, Christine Fandozzi, Jennifer Talaty, Anna Mitselos, Marian Iwamoto, Xiaoyan Chu, Monika Martinho, Corinne Vandermeulen, Luzelena Caro, Xiaobi Huang, Zifang Guo, Jean Francois Denef, Katherine Dunnington, William D. Hanley, Deborah Panebianco, Jan de Hoon, Inge De Lepeleire, Joan R. Butterton, Hwa-Ping Feng, Lihong Du, Patricia Jumes, William L. Marshall, Robert Valesky
The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::437fd6dfa5132f3e6a6fda32702d0e3a
https://lirias.kuleuven.be/handle/123456789/635688
https://lirias.kuleuven.be/handle/123456789/635688
Autor:
Iain P. Fraser, Wendy W. Yeh, Naoto Uemura, Peter W Angus, William B. Smith, Edward Gane, Luzelena Caro, Zifang Guo, Joan R. Butterton, Maureen Ho, Thomas Marbury, Christina Reitmann, Jennifer Talaty, Christine Fandozzi, Marian Iwamoto, Deborah Panebianco, Larissa Wenning
Grazoprevir (GZR) plus elbasvir is an approved treatment for chronic infection with hepatitis C virus (HCV) genotype 1 or 4. HCV infection complications include liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The objective of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5fdd14986b02b15529a39955aaba00e
https://europepmc.org/articles/PMC5700330/
https://europepmc.org/articles/PMC5700330/
Autor:
Luzelena Caro, Dennis Wolford, Zifang Guo, Christine Fandozzi, Jennifer Talaty, Marian Iwamoto, Wendy W. Yeh, Deborah Panebianco, Hwa-Ping Feng, Joan R. Butterton
Publikováno v:
Journal of clinical pharmacology. 58(5)
Elbasvir (EBR)/grazoprevir (GZR) may be coadministered with immunosuppressant drugs in posttransplant people who are infected with hepatitis C virus. The aim of the present study was to assess the safety and pharmacokinetic interactions between EBR a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acc986821fe4a4cecc0004d6360fba83
https://pubmed.ncbi.nlm.nih.gov/29329497
https://pubmed.ncbi.nlm.nih.gov/29329497
Autor:
Narayana I. Narasimhan, John A. Wagner, Nancy G. B. Agrawal, Jacqueline B. McCrea, John Palcza, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Sheila Breidinger, Mark Stroh, Deborah Panebianco, Jennifer Talaty, Amita Patnaik, Michele Trucksis, Richard Lush, Keith Orford, Punam Sandhu
Publikováno v:
The Journal of Clinical Pharmacology. 54:1256-1262
Ridaforolimus, a unique non-prodrug analog of rapamycin, is a potent inhibitor of mTOR under development for cancer treatment. In vitro data suggest ridaforolimus is a reversible and time-dependent inhibitor of CYP3A. A model-based evaluation suggest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd1715dbc428af0874540ad1df932ddd
https://doi.org/10.1002/jcph.331
https://doi.org/10.1002/jcph.331
Autor:
John A. Wagner, Nancy G. B. Agrawal, Evan J. Friedman, Marian Iwamoto, Laura Sepp-Lorenzino, Jennifer Talaty
Publikováno v:
Cancer chemotherapy and pharmacology. 75(2)
MK-0888 is an investigational VEGFR-2 inhibitor with demonstrated potent in vitro enzyme activity. Clinical investigation in healthy volunteers and cancer patients was undertaken to evaluate its pharmacokinetic properties and early safety profile. Ea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f6760e131d6d3d91a422daf14f4d27
https://pubmed.ncbi.nlm.nih.gov/25523287
https://pubmed.ncbi.nlm.nih.gov/25523287
Autor:
Mark, Stroh, Jennifer, Talaty, Punam, Sandhu, Jacqueline, McCrea, Amita, Patnaik, Anthony, Tolcher, John, Palcza, Keith, Orford, Sheila, Breidinger, Narayana, Narasimhan, Deborah, Panebianco, Richard, Lush, Kyriakos P, Papadopoulos, John A, Wagner, Michele, Trucksis, Nancy, Agrawal
Publikováno v:
Journal of clinical pharmacology. 54(11)
Ridaforolimus, a unique non-prodrug analog of rapamycin, is a potent inhibitor of mTOR under development for cancer treatment. In vitro data suggest ridaforolimus is a reversible and time-dependent inhibitor of CYP3A. A model-based evaluation suggest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e637abbd9be4c5f0f8cea12b7349cceb
https://pubmed.ncbi.nlm.nih.gov/24827931
https://pubmed.ncbi.nlm.nih.gov/24827931
Autor:
Kelem Kassahun, Ian McIntosh, Stefan Zajic, Jennifer Talaty, S. Aubrey Stoch, Kenneth A. Koeplinger, Deborah L. Miller, Li Sun, Russell Dixon
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 42(5)
Odanacatib is a selective inhibitor of the cathepsin K enzyme that is expressed in osteoclasts involved in the degradation of bone organic matrix, and is being developed as a novel treatment of osteoporosis. Odanacatib has demonstrated increases in b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e200060aaebb8b2a81a70c2d192154b0
https://pubmed.ncbi.nlm.nih.gov/24553380
https://pubmed.ncbi.nlm.nih.gov/24553380
Autor:
Jennifer Talaty, James M. Reynolds, Daniel Sikkema, Holly A. Lash, Laura B. Rosen, Lisa S. Kierstead
Publikováno v:
Alzheimer's & Dementia. 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f716b193d4ab4b76e8c6ef7087498d10
https://doi.org/10.1016/j.jalz.2008.05.2450
https://doi.org/10.1016/j.jalz.2008.05.2450